DBV Technologies share price drops below €1.77, short selling positions increase
The Châtillon-based biotech extends its downward streak mid-session, in a Paris market also oriented lower. The security crosses a technical threshold that has been monitored for several weeks and remains well below its moving averages.
The €1.77 support level gives way and the share remains below all its moving averages
The share price of DBV Technologies declines by 2.14% to €1.74. During the session, it broke through its support level at €1.77 and remains below it. The share thus stands 15.22% below its 20-day moving average and 43.20% below its 200-day moving average.
The decline reaches 25.28% over one month and 39.53% over three months. The RSI at 30 is at the edge of the oversold zone, which underscores the extent of the recent pullback. The SBF 120 is down 0.77%, but DBV ranks among the most underperforming values in the index, at the bottom of the ranking.
Short positions at 4% of capital, up over 30 days
Declared net short positions reach 4.00% of capital, spread among four funds, according to the declarations reviewed. They have increased by 0.26 percentage points over thirty days, from 3.74%. This level indicates that institutional investors remain positioned to the downside on the security or are seeking to hedge an exposure.
An increase of this magnitude does not signal a sharp reversal, but it aligns with the selling pressure observed for weeks. As a reminder, the company filed its application for biological license with the FDA at the end of September for its peanut allergy patch. When publishing first-half 2026 results on July 16, 2026, it indicated it had cash reserves allowing it to operate until the third quarter of 2027.
